Ajanta Pharma Reports 14% Increase in Q1 FY 2026 Revenue

Ajanta Pharma Ltd., a specialty pharmaceutical formulation company, has reported an excellent performance for the first quarter ended 30 June 2025. The company's revenue from operations stood at Rs. 1,303 crores, marking a 14% increase from the same period last year. The EBITDA stood at Rs. 351 crores, up 6% from Q1 FY 2025, and the profit after tax was Rs. 255 crores, a 4% increase. Excluding the mark-to-market forex loss, the EBITDA stood at Rs. 376 crores, reflecting a 14% growth, and the PAT grew by 12%. The cashflow from operations was Rs. 282 crores, and the free cashflow was Rs. 209 crores. The ROCE stood at a healthy level of 33% and RONW at 26%.